Skip to content

Hydrodilatation, corticosteroids and adhesive capsulitis: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN90567697
Enrollment
88
Registered
2007-10-10
Start date
2003-12-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive capsulitis of the shoulder Musculoskeletal Diseases Adhesive capsulitis

Interventions

Corticosteroid injection with or without a hydrodilatation procedure. Both treatment groups are given the following drugs in each injection: 1. 3 - 4 ml lopromide, Ultravist 300 Schering AG 2. 2 ml

Sponsors

Norwegian Research Council (Norway)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pain in one shoulder for more than 3 months but less than 2 years 2. Reduction in shoulder range of motion 3. Ability to fill out shoulder self-report form

Exclusion criteria

Exclusion criteria: 1. Age below 18 or over 70 2. Various contraindications to injection material 3. Restriction in range of motion for reasons other than capsulitis 4. Mental illness 5. Cancer 6. Current medication with corticosteroids

Design outcomes

Primary

MeasureTime frame
Improvement in Shoulder Pain and Disability Index, measured 6 weeks after the last of three injections.

Secondary

MeasureTime frame
Shoulder range of motion for four different directions of passive and active movements are measured at baseline and then again six weeks after the last of the three injections. The score at follow-up is the outcome measure.

Countries

Norway

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 5, 2026